Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 16;10(9):1116.
doi: 10.3390/antibiotics10091116.

Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci

Benjamin Baëtz  1 , Abdelhakim Boudrioua  1 , Axel Hartke  1 , Caroline Giraud  1
Affiliations
Review

Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci

Benjamin Baëtz et al. Antibiotics (Basel). .

Abstract

Gram positive pathogens are a significant cause of healthcare-associated infections, with Staphylococci and Enterococci being the most prevalent ones. Vancomycin, a last resort glycopeptide, is used to fight these bacteria but the emergence of resistance against this drug leaves some patients with few therapeutic options. To counter this issue, new generations of antibiotics have been developed but resistance has already been reported. In this article, we review the strategies in place or in development to counter vancomycin-resistant pathogens. First, an overview of traditional antimicrobials already on the market or in the preclinical or clinical pipeline used individually or in combination is summarized. The second part focuses on the non-traditional antimicrobials, such as antimicrobial peptides, bacteriophages and nanoparticles. The conclusion is that there is hitherto no substitute equivalent to vancomycin. However, promising strategies based on drugs with multiple mechanisms of action and treatments based on bacteriophages possibly combined with conventional antibiotics are hoped to provide treatment options for vancomycin-resistant Gram-positive pathogens.

Keywords: Enterococci; Gram-positive; Staphylococci; antibiotics; antimicrobial peptides; bacteriophages; nanoparticles; vancomycin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of action of the different traditional and non-traditional strategies against vancomycin resistant Gram-positive pathogens. In bold, name of the molecule.
See this image and copyright information in PMC

References

    1. O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Government of the United Kingdom; London, UK: 2016.
    1. Touat M., Opatowski M., Brun-Buisson C., Cosker K., Guillemot D., Salomon J., Tuppin P., de Lagasnerie G., Watier L. A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study. Appl. Health Econ. Health Policy. 2019;17:381–389. doi: 10.1007/s40258-018-0451-1. - DOI - PMC - PubMed
    1. Cassini A., Högberg L.D., Plachouras D., Quattrocchi A., Hoxha A., Simonsen G.S., Colomb-Cotinat M., Kretzschmar M.E., Devleesschauwer B., Cecchini M., et al. Attributable Deaths and Disability-Adjusted Life-Years Caused by Infections with Antibiotic-Resistant Bacteria in the EU and the European Economic Area in 2015: A Population-Level Modelling Analysis. Lancet Infect. Dis. 2019;19:56–66. doi: 10.1016/S1473-3099(18)30605-4. - DOI - PMC - PubMed
    1. Theuretzbacher U., Bush K., Harbarth S., Paul M., Rex J.H., Tacconelli E., Thwaites G.E. Critical Analysis of Antibacterial Agents in Clinical Development. Nat. Rev. Microbiol. 2020;18:286–298. doi: 10.1038/s41579-020-0340-0. - DOI - PubMed
    1. McKenna M. The Antibiotic Paradox: Why Companies Can’t Afford to Create Life-Saving Drugs. Nature. 2020;584:338–341. doi: 10.1038/d41586-020-02418-x. - DOI - PubMed

LinkOut - more resources